3 results
8-K
EX-99.1
MLTX
MoonLake Immunotherapeutics - Ordinary Shares
11 Mar 24
Regulation FD Disclosure
8:01am
Phase 3 program, marking the first time clinical trial evidence is generated specifically for this demographic.
In rheumatology, MoonLake will also
DEF 14A
MLTX
MoonLake Immunotherapeutics - Ordinary Shares
26 Apr 23
Definitive proxy
4:31pm
or Pacific Islander
White
Two or More Races or Ethnicities
LGBTQ+
Did Not Disclose Demographic Background
Shareholder Recommendations for Directors
- Prev
- 1
- Next